SYRE insider transaction filings
Spyre Therapeutics, Inc. — 43 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-08-10. Screen SYRE transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-08-10 | 4 | Albers Jeffrey W. — Director | Option exercise (M): 5,000 @ $10.39 · Sale (S): 5,000 @ $104.47 · Sale (S): 8,000 @ $104.38 · Sale (S): 10,000 @ $104.68 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2026-08-05 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 800 @ $93.97 · Sale (S): 7,157 @ $95.10 · Sale (S): 5,635 @ $95.93 · Sale (S): 1,392 @ $96.82 · Sale (S): 16 @ $97.46 | EDGAR |
| 2026-08-05 | 4 | Burrows Scott L — Chief Financial Officer | Option exercise (M): 7,500 @ $14.50 · Sale (S): 5,100 @ $95.21 · Sale (S): 2,300 @ $96.30 · Sale (S): 100 @ $97.10 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Burrows Scott L — Chief Financial Officer | Option exercise (M): 7,500 @ $14.50 · Sale (S): 5,775 @ $87.55 · Sale (S): 1,725 @ $88.37 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Sloan Sheldon — Chief Medical Officer | Option exercise (M): 8,334 @ $27.46 · Sale (S): 6,500 @ $87.52 · Sale (S): 1,834 @ $88.34 · Option exercise (M): 8,334 (derivative) @ $0 | EDGAR |
| 2026-07-02 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 10,176 @ $87.44 · Sale (S): 4,234 @ $88.12 · Sale (S): 590 @ $88.91 | EDGAR |
| 2026-06-26 | 4 | Burrows Scott L — Chief Financial Officer | Option exercise (M): 15,000 @ $14.50 · Sale (S): 5,000 @ $87.12 · Sale (S): 10,000 @ $87.14 · Option exercise (M): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | HENDERSON MICHAEL THOMAS — Director | Sale (S): 20,000 @ $100 | EDGAR |
| 2026-06-23 | 4 | Fairmount Funds Management LLC — Director Fairmount Healthcare Fund II L.P. — Director Kiselak Tomas — Director Harwin Peter Evan — Director | Conversion (C): 666,680 · Sale (S): 4,684,781 @ $85.31 · Conversion (C): 16,667 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Sloan Sheldon — Chief Medical Officer | Option exercise (M): 8,333 @ $27.46 · Sale (S): 8,333 @ $75 · Option exercise (M): 8,333 (derivative) @ $0 | EDGAR |
| 2026-06-03 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 3,557 @ $69.40 · Sale (S): 8,149 @ $70.50 · Sale (S): 3,294 @ $71.38 | EDGAR |
| 2026-06-03 | 4 | Burrows Scott L — Chief Financial Officer | Option exercise (M): 7,500 @ $14.50 · Sale (S): 1,801 @ $69.75 · Sale (S): 2,599 @ $70.77 · Sale (S): 3,100 @ $72.06 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Milligan Sandra — Director | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Fairmount Funds Management LLC — Director Kiselak Tomas — Director Fairmount Healthcare Fund II L.P. — Director | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Albers Jeffrey W. — Director | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | HENDERSON MICHAEL THOMAS — Director | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | Stelzer Laurie — Director | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2026-05-29 | 4 | McKenna Mark C. — Director | Grant/award (A): 8,026 (derivative) @ $0 | EDGAR |
| 2026-05-08 | 4 | HENDERSON MICHAEL THOMAS — Director | Sale (S): 2,404 @ $72.57 · Sale (S): 33,513 @ $73.72 · Sale (S): 24,814 @ $74.76 · Sale (S): 19,269 @ $75.35 | EDGAR |
| 2026-05-01 | 4 | Sloan Sheldon — Chief Medical Officer | Option exercise (M): 78,333 @ $27.46 · Sale (S): 21,306 @ $69.53 · Sale (S): 19,656 @ $70.61 · Sale (S): 8,777 @ $71.56 · Sale (S): 12,777 @ $72.94 · Sale (S): 10,358 @ $73.74 · +3 more | EDGAR |
| 2026-05-01 | 4 | Burrows Scott L — Chief Financial Officer | Option exercise (M): 12,500 @ $14.50 · Sale (S): 12,500 @ $71.37 · Option exercise (M): 12,500 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 5,300 @ $69.54 · Sale (S): 3,600 @ $70.77 · Sale (S): 1,000 @ $71.76 · Sale (S): 3,100 @ $73.14 · Sale (S): 1,700 @ $74.23 · Sale (S): 300 @ $74.96 | EDGAR |
| 2026-04-03 | 4 | Burrows Scott L — Chief Financial Officer | Option exercise (M): 7,500 @ $14.50 · Sale (S): 6,200 @ $49.21 · Sale (S): 1,300 @ $49.98 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2026-04-03 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 12,344 @ $49.20 · Sale (S): 2,656 @ $49.92 | EDGAR |
| 2026-04-03 | 4 | Sloan Sheldon — Chief Medical Officer | Option exercise (M): 7,958 @ $21.66 · Sale (S): 7,958 @ $50 · Option exercise (M): 7,958 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Burrows Scott L — Chief Financial Officer | Option exercise (M): 2,500 @ $14.50 · Sale (S): 2,300 @ $40.56 · Sale (S): 200 @ $41.66 · Option exercise (M): 2,500 (derivative) @ $0 | EDGAR |
| 2026-03-03 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 5,900 @ $41.73 · Sale (S): 9,100 @ $42.49 | EDGAR |
| 2026-02-04 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 957 @ $31.82 · Sale (S): 14,043 @ $32.87 | EDGAR |
| 2026-01-23 | 4 | HENDERSON MICHAEL THOMAS — Director | Other (J): 63,227 @ $0 | EDGAR |
| 2026-01-13 | 4 | Burrows Scott L — Chief Financial Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Turtle Cameron — Chief Executive Officer, Director | Grant/award (A): 528,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | Sloan Sheldon — Chief Medical Officer | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-01-13 | 4 | King-Jones Heidy — See Remarks | Grant/award (A): 140,000 (derivative) @ $0 | EDGAR |
| 2026-01-06 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 12,709 @ $30.47 · Sale (S): 2,191 @ $31.79 · Sale (S): 100 @ $32.39 | EDGAR |
| 2025-12-03 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 10,995 @ $28.73 · Sale (S): 4,005 @ $29.83 | EDGAR |
| 2025-11-05 | 4 | Turtle Cameron — Chief Executive Officer, Director | Sale (S): 28,155 @ $23.13 · Sale (S): 16,845 @ $23.66 | EDGAR |
| 2025-09-03 | 4 | Burrows Scott L — Chief Financial Officer | Sale (S): 18,428 @ $16.26 | EDGAR |
| 2025-06-02 | 4 | Fairmount Funds Management LLC — Director Harwin Peter Evan — Director Kiselak Tomas — Director Fairmount Healthcare Fund II L.P. — Director | Grant/award (A): 25,000 (derivative) @ $0 · Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Stelzer Laurie — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Milligan Sandra — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | McKenna Mark C. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | HENDERSON MICHAEL THOMAS — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Albers Jeffrey W. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Spyre Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-04 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-01 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-16 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-13 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events | EDGAR |
| 2026-04-13 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SYRE returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →